Ask the Expert: David White, chief scientific officer of Apnicure: Page 4 of 4

Home >> Ask The Expert >> Ask the Expert: David White, chief scientific officer of Apnicure: Page 4 of 4

July 3, 2013

early results. However, the materials used were not adequately strong/durable to withstand steady tongue movement with breakage of prongs and slippage of tethers. Thus further engineering of such devices will be required before they are likely to be successful. However, the concept seems to be sound.

Pharmacologic approaches to apnea therapy : Over the years many trials of various pharmacologic agents have been attempted in OSA patients with limited to no success. There are not, at this time, any visible such trials ongoing or active work by pharmaceutical companies to develop a drug for the treatment of OSA. However, this could change quickly as our understanding of the neurobiology of the brainstem control of the pharyngeal musculature steadily improves.

From your point of view, what is compelling and special about Apnicure?

With Apnicure we believe that we have a product that can treat a portion of OSA patients (about 40-50%) quite well with a device that will be more comfortable, quieter, and overall more acceptable to these patients. We also believe that the effectiveness of the device can be considerably improved in the near future. Thus our plan is to have a highly effective, well-tolerated therapy for OSA.


RLS News item for

RLS Patients Surveyed

The Willis-Ekbom Disease Foundation and XenoPort, Inc. recently conducted a survey of patients with Restless Legs Syndrome (RLS -- also known as Willis-Ekbom Disease) and found two-thirds of patients (68%) strongly believe physicians need more education about the disease. Three-quarters (73%) of patients report experiencing symptoms daily and only 6% believe that their symptoms are completely controlled by their current medication. Nearly all patients (93%) surveyed indicated that they wished more effective medications were available to treat RLS.